N-丁基-3-甲基-1-丁胺 | 78579-59-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-丁基-3-甲基-1-丁胺
• 英文名称: butyl-isopentyl-amine
• 英文别名: Butyl-isopentyl-amin；1-Butanamine, N-butyl-3-methyl-；N-butyl-3-methylbutan-1-amine
• CAS: 78579-59-6
• 化学式: C₉H₂₁N
• mdl: MFCD11142451
• 分子量: 143.272
• InChiKey: QPIMDFNMIPRTEF-UHFFFAOYSA-N

物化性质

• 保留指数：
  1006

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-丁基-3-甲基-1-丁胺 、 1-萘异硫氰酸酯 生成 N-butyl-N-isopentyl-N'-[1]naphthyl-thiourea
  参考文献：
  名称：

  Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria

  摘要：

  The aim of this study is to compare the efficacy of an angiotensin-converting enzyme inhibitor with a dihydropyridine calcium channel blocker in preventing progression to macroalbuminuria and/or a decline in renal function in normotensive patients with type 1 diabetes and microalbuminuria. Forty-two patients were randomized to treatment with either perindopril, slow-release nifedipine, or placebo. In the first 3 months, drug dosage was titrated to achieve a decrease in diastolic blood pressure of at least 5 mm Hg. Thirty-three patients had a minimum of 24 months' data, and 25 patients were followed up beyond 36 months (mean, 67 +/- 4 months). Patients were studied every 3 months and at the end of the treatment period; those who remained normotensive discontinued therapy and were followed up for an additional 3 months. Baseline geometric mean albumin excretion rates (AERs) were as follows: perindopril, 66 mug/min; nifedipine, 59 mug/min; and placebo, 66 mug/min. During the first 3 years, 7 of the perindopril-treated but none of the placebo or nifedipine-treated patients reverted to normoalbuminuria (P < 0.01). Median AERs at 3 years of treatment in each group were 23 g/min for perindopril, 122 mug/min for nifedipine, and 112 mug/min for placebo patients (P < 0.01). in patients with more than 3 years' follow-up, median AERs decreased by 45% in the first year and then stabilized in the perindopril group, but increased by 17.6% in the nifedipine group and 27.6% in the placebo group (P < 0.03) in the first year, then increased progressively. In these same patients, there was a significant decline in glomerular filtration rate in the nifedipine group (-7.8 +/- 1.8 mL/min/1.73 m(2)/y), but not in the other two groups (perindopril, -1.0 +/- 1.2 mL/min/1.73 m(2)/y; placebo, -1.3 +/- 1.1 mL/min/1.73 m(2)/y; P = 0.004). At the end or the study, cessation of treatment for 3 months was associated with a doubling of AERs in the perindopril-treated group, but no change in the other two groups (P < 0.001). In conclusion, long-term perindopril therapy is more effective than nifedipine or placebo in delaying the progression of diabetic nephropathy and reducing AER to the normoalbuminuric range (<20 mug/min) in normotensive patients with type I diabetes and microalbuminuria. (C) 2000 by the National Kidney Foundation, Inc.

  DOI：

  10.1016/s0272-6386(05)80003-4
• 作为产物：
  描述：

  N-isoamylidenebutylamine 在 乙醇 、 铂 作用下， 生成 N-丁基-3-甲基-1-丁胺
  参考文献：
  名称：

  Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria

  摘要：

  The aim of this study is to compare the efficacy of an angiotensin-converting enzyme inhibitor with a dihydropyridine calcium channel blocker in preventing progression to macroalbuminuria and/or a decline in renal function in normotensive patients with type 1 diabetes and microalbuminuria. Forty-two patients were randomized to treatment with either perindopril, slow-release nifedipine, or placebo. In the first 3 months, drug dosage was titrated to achieve a decrease in diastolic blood pressure of at least 5 mm Hg. Thirty-three patients had a minimum of 24 months' data, and 25 patients were followed up beyond 36 months (mean, 67 +/- 4 months). Patients were studied every 3 months and at the end of the treatment period; those who remained normotensive discontinued therapy and were followed up for an additional 3 months. Baseline geometric mean albumin excretion rates (AERs) were as follows: perindopril, 66 mug/min; nifedipine, 59 mug/min; and placebo, 66 mug/min. During the first 3 years, 7 of the perindopril-treated but none of the placebo or nifedipine-treated patients reverted to normoalbuminuria (P < 0.01). Median AERs at 3 years of treatment in each group were 23 g/min for perindopril, 122 mug/min for nifedipine, and 112 mug/min for placebo patients (P < 0.01). in patients with more than 3 years' follow-up, median AERs decreased by 45% in the first year and then stabilized in the perindopril group, but increased by 17.6% in the nifedipine group and 27.6% in the placebo group (P < 0.03) in the first year, then increased progressively. In these same patients, there was a significant decline in glomerular filtration rate in the nifedipine group (-7.8 +/- 1.8 mL/min/1.73 m(2)/y), but not in the other two groups (perindopril, -1.0 +/- 1.2 mL/min/1.73 m(2)/y; placebo, -1.3 +/- 1.1 mL/min/1.73 m(2)/y; P = 0.004). At the end or the study, cessation of treatment for 3 months was associated with a doubling of AERs in the perindopril-treated group, but no change in the other two groups (P < 0.001). In conclusion, long-term perindopril therapy is more effective than nifedipine or placebo in delaying the progression of diabetic nephropathy and reducing AER to the normoalbuminuric range (<20 mug/min) in normotensive patients with type I diabetes and microalbuminuria. (C) 2000 by the National Kidney Foundation, Inc.

  DOI：

  10.1016/s0272-6386(05)80003-4

文献信息

• Synthesis of Secondary Aminesby Reduction of α-Amidoalkylphenyl Sulfones with SodiumAcetoxyborohydride
  作者：Marino Petrini、Michela Mataloni、Roberto Profeta

  DOI：10.1055/s-2003-39895

  日期：——

  α-Amidoalkylphenyl sulfones are stable precursors of reactive N-acylimines and can be fully reduced to the corresponding secondary amines using sodium acetoxyborohydride in dioxane at reflux.

  α-酰胺基烷基苯基砜是反应性 N-酰基亚胺的稳定前体，可以在回流的二恶烷中使用乙酰氧基硼氢化钠完全还原为相应的仲胺。
• Ophthalmic Compositions for Treating Ocular Hypertension
  申请人：Doherty James B.

  公开号：US20090062280A1

  公开（公告）日：2009-03-05

  This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

  本发明涉及在治疗青光眼和其他导致患者眼内压升高的疾病中使用强效钾通道阻滞剂或其配方。本发明还涉及使用这些化合物在哺乳动物，特别是人类的眼中提供神经保护作用。
• Novel Pyrimidine Imidazole Amines as Modulators of Kinase Activity
  申请人：Merck Patent GmbH

  公开号：US20150225371A1

  公开（公告）日：2015-08-13

  The invention provides novel imidazole amine compounds according to formula (I) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.

  该发明提供了根据式(I)的新型咪唑胺化合物、其制备方法以及用于治疗高增殖性疾病，如癌症的用途。
• AMINOALCOHOL LIPIDOIDS AND USES THEREOF
  申请人：Mahon Kerry Peter

  公开号：US20100331234A1

  公开（公告）日：2010-12-30

  Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these aminoalcohol lipidoid compounds, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive lipidoids and polynucleotide have been prepared. The inventive lipidoids may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.

  本文介绍了通过将胺与环氧末端化合物反应制备氨基醇脂质体的方法。还提供了从商业起始材料制备氨基醇脂质体的方法。氨基醇脂质体可以从外消旋或立体化学纯的环氧化合物制备。氨基醇脂质体或其盐形式最好是可生物降解和生物相容的，并可用于各种药物递送系统。由于这些氨基醇脂质体化合物的氨基基团，它们特别适用于多核苷酸的递送。已制备包含发明性脂质体和多核苷酸的复合物、胶束、脂质体或颗粒。发明性脂质体还可用于制备药物递送的微粒。鉴于它们缓冲其周围环境pH值的能力，它们特别适用于递送不稳定的药物。
• Benzimidazole derivatives and their use as a medicament
  申请人：Poitout Lydie

  公开号：US20090170922A1

  公开（公告）日：2009-07-02

  A subject of the present application is new benzimidazole derivatives of formula in which A, Y, R 1 , R 2 , R 3 and R 4 represent different variable groups. These products have an antagonist activity of GnRH (Gonadotropin-Releasing Hormone). The invention also relates to pharmaceutical compositions containing said products and their use for the preparation of a medicament.

  本申请的主题是公式中A、Y、R1、R2、R3和R4代表不同变量基团的新苯并咪唑衍生物。这些产物具有GnRH（促性腺激素释放激素）的拮抗活性。本发明还涉及含有所述产物的制药组合物及其用于制备药物的用途。